Prospects for the Primary Prevention of Myocardial Infarction and Stroke

Journal of Cardiovascular Pharmacology and Therapeutics - Tập 24 Số 3 - Trang 207-214 - 2019
Madison Caldwell1, Lisa Martínez1, Jennifer Foster1, Dawn Harris Sherling1, Charles H. Hennekens1
1Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, USA

Tóm tắt

Cardiovascular disease (CVD), principally myocardial infarction (MI) and stroke, is the leading clinical and public health problem in the United States and is rapidly becoming so worldwide. Their primary prevention is promising, in theory, but difficult to achieve in practice. The principal modalities that have demonstrated efficacy include therapeutic lifestyle changes (TLCs) and adjunctive drug therapies under the guidance of the health-care provider and tailored to the individual patient. The prevention and treatment of the pandemic of overweight and obesity and lack of regular physical activity, both of which are alarmingly common in the United States, prevention and treatment of hypertension, avoidance and cessation of cigarette smoking, adoption and maintenance of a healthy diet, and avoidance of heavy alcohol consumption all have proven benefits in decreasing the risks of a first MI and stroke as well as other clinical manifestations of CVD. Although adoption of TLCs would avoid the need for adjunctive drug therapies in many primary prevention subjects, this strategy is difficult to achieve or maintain for most and may be insufficient for many, especially those at high risk with metabolic syndrome. The criteria for metabolic syndrome, affecting over 40% of the adult population older than 40 in the United States, include overweight or obesity, dyslipidemia, hypertension, and insulin resistance, a precursor of diabetes. The adjunctive therapies of proven benefit in the primary prevention of MI and stroke include statins, blood pressure medications, aspirin, and drugs to treat insulin resistance and hyperglycemia. Fortunately, even for patients who prefer prescription of pills to proscription of harmful lifestyles, these drug therapies still have net benefits. The adoption and maintenance of TLCs and adjunctive drug therapies into clinical practice will reduce both the incidence of and mortality from a first MI and stroke as well as other major clinical manifestations of CVD.

Từ khóa


Tài liệu tham khảo

10.1161/CIR.0000000000000558

10.1001/jamacardio.2016.1326

10.1161/01.str.0000437068.30550.cf

Al-Khatib S, 2017, J Am College Cardiol

American Heart Association Statistics Committee and Stroke Statistics Subcommittee, 2013, Circulation, 129, e28

10.1016/j.amjmed.2012.06.018

10.1056/NEJM199003293221303

10.1016/S0140-6736(09)60318-4

10.1161/STR.0000000000000046

10.7326/0003-4819-155-7-201110040-00006

10.1161/circ.106.25.3143

10.5888/pcd14.160287

10.1177/1074248416686187

10.1016/j.jacc.2010.05.034

10.1159/000444785

US Department of Health and Human Services, 2008, 2008 Physical Activity Guidelines for Americans

10.1161/01.STR.0000091843.02517.9D

10.1056/NEJM199908263410904

Clarke TC, 2017, Natl Cent Health Stat, 2, 1

US Department of Health and Human Services, 2014, The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General

10.1056/NEJM199106063242303

10.7326/0003-4819-145-11-200612050-00142

10.1016/j.amjmed.2016.11.015

10.1056/NEJMoa1200303

10.1016/S0140-6736(06)68069-0

10.1056/NEJMoa1800389

10.4158/EP14279.CS

10.1001/archinte.1997.00440220083011

10.1056/NEJM199505113321901

10.1016/S0140-6736(18)31310-2

10.3920/978-90-8686-821-6_9

10.1056/NEJMoa0807646

10.1016/j.amjmed.2018.03.034

10.1016/j.jacc.2013.11.002

10.1161/CIRCULATIONAHA.117.032582

10.1001/jama.2013.284427

10.1016/0140-6736(90)90944-Z

10.1056/NEJMoa1511939

10.7326/M15-2223

10.1056/NEJM198801283180431

10.1056/NEJM198907203210301

10.1056/NEJMoa050613

10.1016/S0140-6736(09)60503-1

10.1056/NEJMoa1804988

10.1016/S0140-6736(18)31924-X

McNeil JJ, 2018, N Engl J Med, 379, 1529, 10.1056/NEJMoa1804988

10.1001/jama.2009.1756

10.1177/107424840200700203

10.1001/archinte.164.1.40

Cook NR, 1999, MedGenMed, 1, 1

10.1161/CIRCULATIONAHA.105.539528

Hennekens CH, 2014, Am J Manag Care, 20, 357

10.2337/diacare.25.3.471

10.2337/dc18-S002

10.7326/M15-2345

10.1001/jama.2011.322

Thông tin
Thông tin xuất bản

Journal of Cardiovascular Pharmacology and Therapeutics

Tập 24 Số 3

207-214

Thông tin tác giả